Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01189604
Other study ID # D0092C00001
Secondary ID
Status Completed
Phase Phase 2
First received August 25, 2010
Last updated December 15, 2011
Start date August 2010
Est. completion date November 2010

Study information

Verified date December 2011
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Japan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

Phase IIB study to find the optimal dose rate range of propofol to maintain minimal-to-moderate sedation for diagnostic gastrointestinal endoscopy and gastrointestinal polypectomy.


Recruitment information / eligibility

Status Completed
Enrollment 123
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Male or female (females of child bearing potential to confirm not pregnant via test or contraception)

- Be undergoing a non-emergent esophagogastroduodenoscopy (EGD) or colonoscopy, including polypectomy that shall be completed within 1 hour

Exclusion Criteria:

- American Society of Anesthesiologists (ASA) grade III, IV V and VI

- Baseline oxygen saturation<90% (room air)

- Body Mass Index (BMI) >=35

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Intervention

Drug:
Placebo
Infusion of placebo, same infusion rates as for arm 2
ICI35,868 (propofol)
Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
ICI35,868 (propofol)
Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
ICI35,868 (propofol)
Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
ICI35,868 (propofol)
Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
ICI35,868 (propofol)
Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
ICI35,868 (propofol)
Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute

Locations

Country Name City State
Japan Research Site Isesaki Gunma
Japan Research Site Moriya Ibaragi

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Johnson & Johnson K.K. Medical Company

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score 2 Minutes From Beginning of Maintenance Period The MOAA/S is a 6-point ordinal scale measuring a patient's level of sedation. Scores range from 0 (No response to painful stimulus [trapezius squeeze]) to 5 (Responds readily to name spoken in normal tone [awake]). MOAA/S scores were classified as 0-1, 2-4 and 5. 2 minutes from the beginning of the maintenance period No
Primary Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score 4 Minutes From Beginning of Maintenance Period The MOAA/S is a 6-point ordinal scale measuring a patient's level of sedation. Scores range from 0 (No response to painful stimulus [trapezius squeeze]) to 5 (Responds readily to name spoken in normal tone [awake]). MOAA/S scores were classified as 0-1, 2-4 and 5. 4 minutes from the beginning of the maintenance period No
Secondary Patient Satisfaction With Sedation Instrument (PSSI) Questionnaire The PSSI is a 100-point visual analog scale measuring a patient's satisfaction with sedation. Scores range from 0 (Very dissatisfied) to 100 (Very satisfied). 24 - 48 hours after completion of the procedure No
Secondary Blood Concentrations of Propofol Blood concentration of ICI35,868 (propofol) At the end of the initiation period and every 2 minutes during the maintenance period No
Secondary Modified Observers Assessment of Alertness/Sedation (MOAA/S) at End of Initiation Period The MOAA/S is a 6-point ordinal scale measuring a patient's level of sedation. Scores range from 0 (No response to painful stimulus [trapezius squeeze]) to 5 (Responds readily to name spoken in normal tone [awake]). MOAA/S scores were classified as 0-1, 2-4 and 5. Last measurement in maintenance period (3 minutes for arms 1-5; 1 minute for arm 6, 5 minute for arm 7) No
See also
  Status Clinical Trial Phase
Recruiting NCT05222048 - Endoscopy Needs of People in Suichang County, Lishui City, Zhejiang Province, China
Completed NCT05103696 - A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients N/A
Completed NCT04123821 - The Routine Use of Nasopharyngeal Airway in the Setting of Monitored Anesthesia Care During Gastrointestinal Endoscopy N/A
Recruiting NCT04879771 - Comparison of Receiving Painless Gastrointestinal Endoscopy in the Morning or Afternoon on Postoperative Sleep Quality
Completed NCT01941888 - Propofol TCI Administered by Gastroenterologists During Endoscopy: a Randomized Double Blind Controlled Study Phase 4
Completed NCT03829293 - High-Flow Nasal Oxygenation Versus Standard Oxygenation in Gastrointestinal Endoscopy With Sedation. N/A
Completed NCT00952458 - Bispectral Index Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography N/A
Completed NCT03669068 - Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: THE ENDOHEM REGISTRY
Completed NCT03632330 - Sedation Of Adult Patients Undergoing Gastrointestinal Endoscopy: A Network Meta-analysis
Completed NCT05485064 - Moderate Sedation Combined With Acupuncture Anesthesia in Gastroscopy and Colonoscopy on Screening Research N/A
Completed NCT05414435 - Informed Consent in Endoscopy: Read, Understood or Merely Signed?
Completed NCT04656964 - Comparison Between Remimazolam Tosilate and Midazolam in Elderly Patients Undergoing Gastrointestinal Endoscopy N/A